18TH ANNUAL PAIN THERAPEUTICS SUMMIT

Oct 28 – Oct 29, 2024

Latest News

Thu Dec 19, 2024 09:00 am

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

View All News

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Past Events

October 28, 2024 10:00 AM ET18th Annual Pain Therapeutics Summit


You are about to review presentations, reports and/or filings of MIRA Pharmaceuticals, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. MIRA Pharmaceuticals, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by MIRA Pharmaceuticals, Inc.

All Events

Latest Presentation

All Presentations
Latest Presentation

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024

Earnings Release

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Annual Reports

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

10-Q

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

View 10-K

Company Overview

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA’s noval oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration’s scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

View Our Leadership
View Our Board of Directors

Symbol
NASDAQ: MIRA
Price
$
Volume
Change
{'1d_range' | i8ln tLang}
{scope.data.dayLow | asQHLast tLang}
{scope.data.dayHigh | asQHLast tLang}
{'52weekrange' | i8ln tLang}
{scope.data.week52Low | asQHLast tLang}
{scope.data.week52High | asQHLast tLang}

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

IR Contacts

Company

MIRA Pharmaceuticals, Inc.
1200 Brickell Ave.
Suite 1950 #1183
Miami, FL 33131
United States
T: 786-432-9792
info@mirapharma.com

Investor Relations

MIRA Pharmaceuticals, Inc.
T: 786-432-9792
info@mirapharma.com

Transfer Agent

Equiniti
48 Wall Street, 23rd FL.
New York, NY 10005
T: US 800-401-1957
Canada/US Virgin Islands 800-468-9716
Other Internationl Access Codes
Rohan.bickram@equiniti.com